182 related articles for article (PubMed ID: 1421413)
1. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
Carlo-Stella C; Mangoni L; Almici C; Cottafavi L; Meloni G; Mandelli F; Rizzoli V
Blood; 1992 Nov; 80(9):2412-8. PubMed ID: 1421413
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial.
Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Philip T
Blood; 1992 Sep; 80(5):1149-57. PubMed ID: 1515637
[TBL] [Abstract][Full Text] [Related]
3. Effect of recombinant human granulocyte-macrophage colony-stimulating factor (rh GM-CSF) in patients with lymphoid malignancies receiving unpurged or mafosfamide-purged autografts.
Carlo-Stella C; Mangoni L; Almici C; Meloni G; Mandelli F; Rizzoli V
Behring Inst Mitt; 1991 Dec; (90):69-74. PubMed ID: 1801693
[No Abstract] [Full Text] [Related]
4. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC
Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
[TBL] [Abstract][Full Text] [Related]
5. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.
Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL
Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
7. In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts.
Blazar BR; Kersey JH; McGlave PB; Vallera DA; Lasky LC; Haake RJ; Bostrom B; Weisdorf DR; Epstein C; Ramsay NK
Blood; 1989 Feb; 73(3):849-57. PubMed ID: 2644992
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma.
Link H; Boogaerts MA; Carella AM; Ferrant A; Gadner H; Gorin NC; Harabacz I; Harousseau JL; Hervé P; Holldack J
Blood; 1992 Nov; 80(9):2188-95. PubMed ID: 1421390
[TBL] [Abstract][Full Text] [Related]
9. [Hematopoietic growth factor (GM-CSF) after autologous bone marrow transplantation. A randomized, double-blind, multicenter study in 91 cases of non-Hodgkin's malignant lymphomas].
Gorin NC; Coiffier B; Hayat M; Fouillard L; Kuentz M; Flesch M; Colombat P; Boivin P; Slavin S; Lemarié JC
Presse Med; 1993 Jan; 22(3):109-20. PubMed ID: 8493215
[TBL] [Abstract][Full Text] [Related]
10. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
13. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.
Rabinowe SN; Neuberg D; Bierman PJ; Vose JM; Nemunaitis J; Singer JW; Freedman AS; Mauch P; Demetri G; Onetto N
Blood; 1993 Apr; 81(7):1903-8. PubMed ID: 8461475
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
Laughlin MJ; Kirkpatrick G; Sabiston N; Peters W; Kurtzberg J
Ann Hematol; 1993 Dec; 67(6):267-76. PubMed ID: 7506580
[TBL] [Abstract][Full Text] [Related]
16. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
Nemunaitis J; Rabinowe SN; Singer JW; Bierman PJ; Vose JM; Freedman AS; Onetto N; Gillis S; Oette D; Gold M
N Engl J Med; 1991 Jun; 324(25):1773-8. PubMed ID: 1903847
[TBL] [Abstract][Full Text] [Related]
17. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).
Slavin S; Mumcuoglu M; Landesberg-Weisz A; Kedar E
Bone Marrow Transplant; 1989 Sep; 4(5):459-64. PubMed ID: 2676042
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
[TBL] [Abstract][Full Text] [Related]
20. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution.
Gorin NC; Labopin M; Laporte JP; Douay L; Lopez M; Lesage S; Fouillard L; Isnard F; Jouet JP; Bellal N; Perot C; Van Den Akker J; Bauters F; Najman A
Exp Hematol; 1999 Dec; 27(12):1822-30. PubMed ID: 10641600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
